Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Profit After Tax: 2015-2024

Historic Profit After Tax for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$60.7 million.

  • Insight Molecular Diagnostics' Profit After Tax rose 19.56% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 40.87%. This contributed to the annual value of -$60.7 million for FY2024, which is 118.36% down from last year.
  • Insight Molecular Diagnostics' Profit After Tax amounted to -$60.7 million in FY2024, which was down 118.36% from -$27.8 million recorded in FY2023.
  • In the past 5 years, Insight Molecular Diagnostics' Profit After Tax registered a high of -$27.8 million during FY2023, and its lowest value of -$72.9 million during FY2022.
  • Over the past 3 years, Insight Molecular Diagnostics' median Profit After Tax value was -$60.7 million (recorded in 2024), while the average stood at -$53.8 million.
  • In the last 5 years, Insight Molecular Diagnostics' Profit After Tax soared by 61.89% in 2023 and then slumped by 118.36% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Profit After Tax (Yearly) stood at -$29.9 million in 2020, then tumbled by 114.14% to -$64.1 million in 2021, then declined by 13.74% to -$72.9 million in 2022, then surged by 61.89% to -$27.8 million in 2023, then crashed by 118.36% to -$60.7 million in 2024.